VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
Vistakon, Division of Johnson & Johnson Vision Car · Decision date Sep 2, 2026
What did the FDA decide?
FDA recorded a decision dated 2026-09-02 on supplement P040045/S145 to VISTAKON (senofilcon A) contact lens, clear and visibility tinted with UV blocker, held by Vistakon, Division of Johnson & Johnson Vision Car. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded decision code is OK30. The device falls in the soft contact lens, extended wear category, ophthalmic specialty, product code LPM.
The recorded scope is qualification of an existing manufacturing line to produce these lenses at the facility in Jacksonville, Florida. That describes a manufacturing-line change within the existing application rather than a new approval of the lens system as a whole. The public documentation contains no supporting documents and no document record identifier, so the notice contents, the basis for the decision and any conditions attached to it are not available here. Whether OK30 carries a specific administrative meaning is not stated in the source data.
Clinical performance, labeling and patient-selection information are outside this record and remain in the underlying FDA documentation.
FDA approval order statement
qualification of an existing manufacturing line to produce VISTAKON (senofilcon A) contact lenses, at the manufacturing facility located in Jacksonville, Florida
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040045/S145
- Regulatory pathway
- PMA supplement
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040045. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040045 · Original PMA
VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
P040045/S145 received
Application receipt date recorded by FDA.
P040045/S145 · FDA decision
30-Day Notice
P040045/S146 · Related supplement
VISTAKON (SENOFILCON A) Brand Contact Lenses
P040045/S147 · Related supplement
VISTAKON (senofilcon A) Brand Contact Lenses
Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vistakon, Division of Johnson & Johnson Vision Car | PMA approval | Dec 20, 2005 | FDA | |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA | |
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vistakon, Division of Johnson & Johnson Vision Car
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256
Sources and methodology
- Original FDA record: P040045/S145
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


